Medical Services International to Expand Capacity
14 Juin 2007 - 7:39PM
PR Newswire (US)
EDMONTON, Alberta, June 14 /PRNewswire-FirstCall/ -- Medical
Services International Inc. (OTC:MSITF) is pleased to announce that
the demand for the VScan products has increased so much that we
must increase our production capability. The Company is using
profits from existing sales to begin buying additional equipment
necessary to increase our production capability by 1.5 million kits
by the end of the year. Completion of this expansion will give the
Company overall capacity of 6.8 million as well as expanding the
Research and Development facility in the Unites States. The Company
has also begun looking for a facility to purchase in the United
States that will house the R&D facility. In keeping with its
policy of no bank debt, the company expects to be in a position to
pay cash for the new facility. It is felt that owning our own
facility will add flexibility to our ability to expand in the
future. About VScan The VScan rapid test kit is a single use,
disposable, accurate, cost effective, easy to use, test for the
screening of HIV1&2, Hepatitis B&C, Tuberculosis (TB),
Dengue Fever, West Nile, Syphilis and Prostate Cancer. The kits
cannot be sold in Canada. Medical Services International Inc.
trades in the United States on the NQB Pink Sheets under the symbol
"MSITF". For further information, please contact Robert Talbot at
(780) 430 6363 or http://www.medicalservicesintl.com/ or
http://www.minerva-biotech.com/. NOTE: Certain statements in this
press release are "forward-looking statements" within the meaning
of the Private Securities Act of 1995. Such statements involve
known and unknown risks, uncertainties and other factors that may
cause results to differ materially. Such risks, uncertainties and
other factors include but are not limited to new economic
conditions, risk in product development, market acceptance of new
products and continuing product demand, level of competition and
other factors described in Company reports and other filings with
regulatory bodies. DATASOURCE: Medical Services International Inc.
CONTACT: Robert Talbot for Medical Services International Inc.,
+1-780-430-6363 Web site: http://www.medicalservicesintl.com/
http://www.minerva-biotech.com/
Copyright